However, anti-CD47 antibodies can competitively inhibit CD47’s binding to SIRPα and mediate macrophage phagocytosis, thereby targeting and killing tumor cells, such as those found in NSCLC (Theruvath et al., 2022). The gene discussed is CD47; the disease is neoplasm.